Giant Cell Tumor of Bone

News alerts, weekly reports and conference planners

No biomarker	Giant Cell Tumor of Bone	No biomarker	Giant Cell Tumor of Bone	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1	denosumab Sensitive: A1 - Approval denosumab Sensitive : A1
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone	H3F3A mutation + ARID2 mutation	Giant Cell Tumor of Bone	denosumab Resistant: C4 – Case Studies denosumab Resistant : C4	denosumab Resistant: C4 – Case Studies denosumab Resistant : C4
COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor	COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor	gefitinib + mitoxantrone Sensitive: C4 – Case Studies gefitinib + mitoxantrone Sensitive : C4	gefitinib + mitoxantrone Sensitive: C4 – Case Studies gefitinib + mitoxantrone Sensitive : C4

Associations(5)